Evidence map›Paper›PMID 36622338›Full record

ArticleBlood advances2023

Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study.

Joshua A Fein, Roni Shouval, Jacques-Emmanuel Galimard, Myriam Labopin, Gérard Socié, Jürgen Finke, Jan J Cornelissen, Ram Malladi, Maija Itälä-Remes, Patrice Chevallier and 7 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 8 countries.

Joshua A FeinDepartment of Hematology and Oncology, Weill Cornell Medicine, Cornell University, New York-Presbyterian, New York, NY.ORCID 0000-0001-5441-1516
Roni ShouvalAdult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-9827-8032
Jacques-Emmanuel GalimardHematology Department, Hôpital Saint-Antoine, Paris, France.
Myriam LabopinHematology Department, Hôpital Saint-Antoine, Paris, France.
Gérard SociéHematology and Transplantation Unit, Hôpital Saint Louis, AP-HP, Paris, France.
Jürgen FinkeDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-1799-5927
Jan J CornelissenErasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands.
Ram MalladiCentre for Clinical Haematology, University of Birmingham, Birmingham, United Kingdom.
Maija Itälä-RemesDepartment of Clinical Hematology and Stem Cell Transplant Unit, Turku University Hospital, Turku, Finland.ORCID 0000-0001-5844-1632
Patrice ChevallierDepartment of Clinical Hematology, Nantes University, Nantes, France.
Kim H OrchardWessex Blood and Marrow Transplant and Cellular Therapy Program, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.ORCID 0000-0003-2276-3925
Donald BunjesDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Mahmoud AljurfOncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudia Arabia.
Marie Thérèse RubioDepartment of Hematology and Bone Marrow Transplantation, Hôpitaux de Brabois, Nancy, France.
Jurjen VersluisErasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands.
Mohamad MohtyHematology Department, Hôpital Saint-Antoine, Paris, France.
Arnon NaglerHematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel.
Inserm · FRErasmus MC · NLAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCornell University · USKing Faisal Specialist Hospital & Research Centre · SAMemorial Sloan Kettering Cancer Center · USNantes Université · FRTel Aviv University · ILTurku University Hospital · FIUniversity Hospital Southampton NHS Foundation Trust · GBUniversity Hospital Ulm · DEUniversity of Birmingham · GBUniversity of Freiburg · DE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Older age and a high burden of comorbidities often drive the selection of low-intensity conditioning regimens in allogeneic hematopoietic stem cell transplantation recipients. However, the impact of comorbidities in the low-intensity conditioning setting is unclear. We sought to determine the contribution of individual comorbidities and their cumulative burden on the risk of nonrelapse mortality (NRM) among patients receiving low-intensity regimens. In a retrospective analysis of adults (≥18 years) who underwent transplantation for acute myeloid leukemia in the first complete remission between 2008 and 2018, we studied recipients of low-intensity regimens as defined by the transplantation conditioning intensity (TCI) scale. Multivariable Cox models were constructed to study associations of comorbidities with NRM. Comorbidities identified as putative risk factors in the low-TCI setting were included in combined multivariable regression models assessed for overall survival, NRM, and relapse. A total of 1663 patients with a median age of 61 years received low-TCI regimens. Cardiac comorbidity (including arrhythmia/valvular disease) and psychiatric disease were associated with increased NRM risk (hazard ratio [HR], 1.54; 95% confidence interval [CI], 1.13-2.09 and HR, 1.69; 95% CI, 1.02-2.82, respectively). Moderate pulmonary dysfunction, though prevalent, was not associated with increased NRM. In a combined model, cardiac, psychiatric, renal, and inflammatory bowel diseases were independently associated with adverse transplantation outcomes. These findings may inform patient and regimen selection and reinforce the need for further investigation of cardioprotective transplantation approaches.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdultComorbidityHumansMiddle AgedRetrospective StudiesTransplantation ConditioningTransplant Recipients

Identifiers

PMID36622338
PMCPMC10206431
OpenAlexW4313857839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.